IMR Press / EJGO / Volume 43 / Issue 2 / DOI: 10.31083/j.ejgo4302042
Open Access Case Report
Uterine lipoleiomyoma: a benign entity with malignant transformation potential?
Show Less
1 Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, 300052 Tianjin, China
2 Department of Gynecology and Obstetrics, The First Affiliated Hospital of Henan University of Science and Technology, 471003 Luoyang, Henan, China
3 Department of Gynecology and Obstetrics, Zhejiang Hospital, 310030 Hangzhou, Zhejiang, China
*Correspondence: liuguoyan211@126.com (Guoyan Liu)
These authors contributed equally.
Academic Editor: Enrique Hernandez
Eur. J. Gynaecol. Oncol. 2022 , 43(2), 363–367; https://doi.org/10.31083/j.ejgo4302042
Submitted: 9 January 2021 | Revised: 9 February 2021 | Accepted: 23 February 2021 | Published: 15 April 2022
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

Background: Uterine lipoleiomyoma is a rare lipomatous variant of uterine leiomyoma composed of a variable mixture of mature smooth muscle cells and adipocytes, typically found in peri or postmenopausal women. Malignancies arising from the tumor have rarely been reported though it is considered benign. Cases: We present three cases of uterine lipoleiomyoma and review literature to explore its etiology, characteristics, diagnosis and malignant transformation potential. Conclusion: Imaging examinations especially magnetic resonance imaging (MRI) play an important role in preoperative diagnosis. For large size and rapid growth of lipoleiomyoma, malignant transformation potential should be considered and surgery is required. Follow-up is still necessary.

Keywords
Differential diagnosis
Magnetic resonance imaging
Malignancy
Ultrasound
Uterine lipoleiomyoma
1. Introduction

Uterine lipoleiomyoma is a rare benign type of uterine leiomyoma with an incidence ranging from 0.03% to 0.2%, which is most common in the uterine corpus [1]. Malignancies arising from the tumor have rarely been reported though it is considered benign [2, 3]. Herein, we report three cases of uterine lipoleiomyoma in our institution with a literature review for deeply understanding of etiology, characteristics, differential diagnosis and malignant transformation potential of the tumor.

2. Case reports and literature review

Three cases of uterine lipoleiomyoma were identified in Tianjin Medical University General Hospital. Serum level of cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) of all patients were within normal value. All patients have a good recovery without recurrence.

2.1 Case 1

A 58-year-old postmenopausal woman presented with complaints of increased urinary frequency. Serum level of total cholesterol was a little higher than normal value. She had a history of left thyroidectomy and thyroid function was well-controlled by oral administration of Levothyroxine Sodium Tablets. Transvaginal ultrasound (TVS) showed a well-circumscribed, media-hyperechoic mass (Fig. 1a). Pelvic magnetic resonance imaging (MRI) showed a well-defined mass with heterogeneous isointense on T1 which was suppressed on fat suppressed (FS) image and hypointense on T2 weighted image (Fig. 1b–d). The patient underwent a total laparoscopic hysterectomy (TLH) and bilateral salpingo-oophorectomy (BSO), a yellowish mass measuring 10 × 7 × 8 cm was found (Fig. 1e,f). Histology showed an admixture of mature smooth muscle cells and adipocytes without cytologic atypia, necrosis, calcification, or immature lipoblasts (Fig. 1g). Immunohistochemical staining showed positive desmin in smooth muscle cells and adipocytes (Fig. 1h).

Fig. 1.

Imaging, specimen and histopathological findings of case 1. (a) TVS showing a well-circumscribed, media-hyperechoic mass arising from the anterior aspect of the uterine corpus. (b) T2-weighted image showing a hypointense mass compressing the uterine cavity. (c,d) T1-weighted image showing a well-circumscribed heterogeneous isointense mass arising from anterior wall to the uterus and a low suppressed signal intensity on T1 fat suppressed image. (e,f) The gross specimen showing a well-defined elastic mass measuring 10 × 7 × 8 cm and a yellowish appearance on the cut surface. (g) Spindle-shaped smooth muscle cells mixed with mature adipose tissue (H&E × 100). (h) Immunostaining showing desmin (+) of smooth muscle cells and adipocytes (H&E × 100).

2.2 Case 2

A 58-year-old postmenopausal woman presented with vaginal bleeding to hospital. Serum level of total cholesterol was a little higher than normal value. TVS revealed a media-hyperechoic mass arising from the fundus uteri (Fig. 2a). The patient underwent TLH and BSO, and a yellow oval-shaped mass measuring 1.5 × 1.4 × 1.7 cm was found (Fig. 2b). Uterine lipoleiomyoma with uterine endometrial hyperplasia changes was made for diagnosis by histopathology (Fig. 2c).

Fig. 2.

Imaging, specimen and histopathological findings of case 2 and 3. (a) TVS showing a well-circumscribed heterogeneous hyperechoic mass from the fundus uteri. (b) The gross specimen showing a well-defined yellow oval-shaped mass measuring 1.5 × 1.4 × 1.7 cm. (c) Mature adipose tissue mixed with spindle-shaped smooth muscle cells (H&E × 100). (d) TVS showing a heterogeneous hyperechoic mass arising from the inferior aspect of the uterine corpus growing into uterine cavity. (e) The gross specimen showing a well-defined soft yellow mass measuring 5.7 × 5.2 × 3.4 cm. (f) Mature adipose tissue mixed with smooth muscle cells (H&E × 100).

2.3 Case 3

A 45-year-old perimenopausal woman presented with complaints of hypermenorrhea, who had a history of uterine leiomyoma for 2 years. Multiple hypoechoic masses and a media-hyperechoic mass arising from the inferior aspect of the uterine corpus were shown on TVS (Fig. 2d). The patient underwent a total abdominal hysterectomy (TAH) and bilateral salpingectomy (BS), and a well-defined soft yellowish mass measuring 5.7 × 5.2 × 3.4 cm was found (Fig. 2e). Histopathology report showed uterine lipoleiomyoma for diagnosis (Fig. 2f).

The electronic medical database PubMed was used for research, combining the following terms: (“lipoleiomyoma” or “myolipoma”) and (“uterine” or “uterus”). Up to now, approximately 240 cases of lipoleiomyoma of uterine corpus have been reported in English literature. Relative complete clinical and imaging data (the items listed in Table 1) were available in 24 cases that include manifestation, medical history, imaging examinations (ultrasound and at least one of computed tomography (CT) or MRI), treatment, etc. To better understand the characteristics of this tumor, herein we make a literature review with these 24 cases [1, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24] plus our 3 cases.

Table 1.Characteristics of 27 cases of lipoleiomyoma in the uterine corpus.
Total recorded number
Mean (range) age (n = 27), y 60 (39–80)
Menopause (n = 27), n (%)
Yes 21 (77.8)
No 6 (22.2)
Symptom (n = 27), n (%)
Abdominal/Pelvic pain 13 (48.1)
Abnormal uterine bleeding/discharge 5 (18.5)
Hypermenorrhea 3 (11.1)
Abdominal distension/discomfort 7 (25.9)
Frequency of micturition 2 (7.4)
Asymptomatic 3 (11.1)
CA125 (n = 27), n (%)
Higher 2 (7.4)
Location (n = 27), n (%)
Submucosal 4 (14.8)
Intramural 18 (66.7)
Subserosal 5 (18.5)
Ultrasound (n = 27), n (%)
Echogenic 3 (11.1)
Homogenous hyperechoic 17 (63.0)
Heterogeneous hyperchoic 7 (25.9)
CT (n = 19), n (%)
Homogenous hypodense 7 (36.8)
Heterogeneous hypodense 12 (63.2)
MRI
T1/T2 (n = 16), n (%)
Homogenous high signal 8 (50.0)
Heterogeneous iso-signal 1 (6.2)
Heterogeneous high signal 7 (43.8)
T1/T2 with FS (n = 9), n (%)
Suppressed signal 9 (100)
Treatment (n = 27), n (%)
Hysterectomy + BSO/BS 18 (66.7)
Myomectomy 1 (3.7)
Hysteroscopy 1 (3.7)
No treatment 7 (25.9)
Mean (range) size (maximal dimension, n = 25), cm 7.5 (1.7–18.0)
Prognosis (n = 14), n (%)
Recurrence 0 (0)
No recurrence 14 (100)
CA125, Cancer antigen 125; CT, Computed tomography; MRI, Magnetic resonance imaging; FS, Fat suppression; BS, Bilateral salipingectomy; BSO, Bilateral salpingo-oophorectomy.

Table 1 showed characteristics of 27 cases of lipoleiomyoma in the uterine corpus. The age at diagnosis of uterine lipoleiomyoma ranged from 39 to 80 (mean 60) years. The symptoms were similar to those of leiomyoma. CA125 levels of two patients were higher than normal range, and they were preoperatively misdiagnosed as liposarcoma and leiomyosarcoma respectively [12, 14]. Seventeen of the 27 patients showed a well-defined homogenous hyperechoic mass on ultrasound. Nineteen patients underwent CT that the result of a well-circumscribed heterogeneous hypodense mass accounted for 63% of all. A half of 16 patients showed a heterogeneous signal mass, and the signal suppressed in all FS images on MRI. Patients underwent a variety of treatments. Seven patients didn’t choose invasive excisions mainly due to the preoperative diagnosis. Two of the seven patients were diagnosed by histological examination of a core needle biopsy specimen and another five only based on clinical and imaging features. Follow-up was available for 14 patients and no recurrence was reported. But an 80-year-old patient preoperatively misdiagnosed as a liposarcoma died of catastrophic postoperative complication 10 days after surgery [12]. This case suggests that surgery should be seriously considered for elderly and high-risk patients despite suspicious malignancy, and a sample needle biopsy may be helpful to identify [13, 16].

3. Discussion

The histogenesis of lipoleiomyoma is controversial. Traditionally, the adipose tissue element of lipoleiomyoma is thought to be derived from degeneration of leiomyoma. Recently, immunohistochemical studies support a complex histogenesis of lipoleiomyoma that it might arise from lipomatous metaplasia of the smooth muscle cells of leiomyoma, or the direct transformation of smooth muscle cells into adipocytes that may originate from the transformation of a totipotent mesenchymal cell [1, 5, 25]. Positive vimentin, estrogen (ER) and progesterone (PR) can be seen in both elements, as well as negative pancytokeratin (AE1/3, CAM5.2), MDM2, CDK4, p53, CD34 and KIT. Respectively, the adipose cells are strongly positive for S-100 protein, and strongly positive α-SMA and desmin are found in the smooth muscle cells [26].

There have been some findings reported about the etiology. Hyperestrogenic associated lesions coexist with the lipoleiomyoma like other leiomyoma in some patients, such as endometriosis, adenomyosis, endometrial hyperplasia, polyps and related malignancies, which may contribute to the development of lipoleiomyoma [25]. Lipoleiomyoma may also be associated with some metabolic disorders such as hyperlipidemia, hypothyroidism, and diabetes mellitus [2, 25]. It is consistent with our review findings that nearly 30% of patients were related to abnormal lipid metabolism and most of them were postmenopausal [4, 8, 11, 14], which suggests that increased risk of abnormal lipid metabolism associated with oestrogen deficiency after menopause transition may facilitate the development of lipoleiomyoma.

However, whether malignant transformation can occur in lipoleiomyoma is controversial. Four cases have been reported about uterine liposarcomas or leiomyosarcomas with lipoleiomyomatous component up to now [2, 3]. In these four malignancies, patients ranged in age from 49 to 70 (mean 62) years and presented with abnormal uterine bleeding (1/2), enlarged uterus (3/4) and lower abdominal mass (1/4). TAH and BSO were performed for all patients. Partial vaginectomy and appendectomy were also respectively performed for the metastasized case and the case with a carcinoid tumor in the appendix. In gross, all tumors were centered in the myometrium ranged in size from 10 to 18.5 (mean 12.4) cm with well-circumscribed pushing margins. One tumor had a vaginal metastasis nodule in size of 3 cm [2], other findings included multiple leiomyomas, ovarian stromal hyperthecosis, and a carcinoid tumor in the appendix [3].

Histopathologically, in addition to the malignant features of liposarcoma or leiomyosarcoma, three of the malignancies merged imperceptibly with a lipoleiomyoma (two typical and one atypical), another was consistent with a well-demarcated infarcted lipoleiomyoma contained by it. In three cases, the findings were further confirmed by immunohistochemical analysis using S100, desmin, h-caldesmon and MDM2. Follow-up was available for three patients, and they were alive and free of disease for 1, 2 and 20 years after surgery respectively at the last time [3]. Tumor markers and imaging findings were not mentioned with emphasis in these four cases, but some related features of liposarcoma and leiomyosarcoma have been reported in other literature that is helpful for the differential diagnosis. Well-differentiated liposarcoma may confound diagnosis of lipoleiomyoma because of the fatty nature on MRI. T1-weighted images show a predominantly high signal mass containing multiple nonuniformly thickened or partially nodular septa of low signal in the well-differentiated liposarcoma of uterus. The septum is enhanced on T1-weighted, fat-saturated, and gadolinium-enhanced imaging [27]. Reportedly, well-differentiated liposarcomas are diagnosed with 100% sensitivity and 83% specificity when the following three features are present on MRI: a thickened or nodular septum (generally >2 mm), areas of enhancement, and areas of high signal on T2-weighted imaging [28]. Leiomyosarcomas (LMS) show small heterogenous focal/multifocal areas of increased high signal on T1-weighted images and non-suppressed signal on FS images, which suggests focal hemorrhage or coagulative necrosis in LMS rather than intralesional fatty tissue of lipoleiomyoma. Additionally, an area of central non-enhancement on contrast-enhanced MRI can also differentiate hemorrhage or necrosis in LMS, as well as higher grade liposarcoma. There is no consensus on the utility of CA125 in the diagnosis of uterine sarcoma [29]. A high serum lactate dehydrogenase (LDH) level may be related to LMS but lack specificity [30]. The pathogenesis of malignancy transformation in lipoleiomyoma is unclear. The origin of sarcomas arising from preexisting leiomyomas was confirmed by positional relationship and certain genetic alterations between the two different tumor components [31, 32]. Some studies have shown that leiomyoma-like areas can be seen associated with uterine leiomyosarcoma that nearly all the genetic aberrations found in leiomyoma-like areas were also found in the corresponding uterine leiomyosarcoma areas, raising the possibility of precursor lesions for uterine leiomyosarcoma [33]. Similarly, sarcomatous transformation from lipoleiomyoma may be the most likely origin of these 4 cases. Sarcomas arising from lipoleiomyoma is difficult to diagnose preoperatively, especially in the early stage. In addition, lipoleiomyoma should be differentiated from other uterine wall tumors with malignant potential, such as uterine perivascular epithelioid cell tumor (PEComa), which reveals similar heterogeneous echogenicity but significant vascular modifications characterized by a rich central vascular network in Color Doppler [34]. Sample needle biopsy can be considered, and a preoperative diagnosis of the tumor may be improved using a combination of clinical, imaging and histological findings [13, 16, 30]. But the biopsy specimens are very small and the diagnosis may be underestimated. In view of the potential malignancy risk, if surgical treatment was opted for, intraoperative frozen section should be emphasized as it is a very useful aid to decide the extent of surgical management and postoperative histological examinations should be carefully performed. In addition, it is worth discussing whether aggressive surgery should be considered more for treatment options of the giant lipoleiomyomas (10 cm) or rapid growth cases. Follow-up with clinical and imaging features is still necessary especially for patients without radical operations. There have only four cases been reported about malignant transformation in lipoleiomyomas and further studies remain to be done.

4. Conclusions

Uterine lipoleiomyoma is a rare benign lipomatous variant of uterine leiomyoma, typically found in peri or postmenopausal women. The histogenesis of the tumor remains controversial. Symptoms are generally similar to uterine leiomyoma. Imaging examinations especially MRI played an important role in preoperative differential diagnosis. There is no reliable method of preoperative diagnosis of uterine lipoleiomyoma. For large size and rapid growth of lipoleiomyoma, malignant transformation potential of the tumor should be considered and surgery is required. Follow-up is still necessary.

Author contributions

GL and YW conceived the report. YW and XZ contributed to manuscript writing, YS and LW were involved in the data collection. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The patients have given their written informed consent to publish their case. All clinical information and images used in this paper were approved by the ethical committee of Tianjin Medical University General Hospital.

Acknowledgment

We would like to thank Xiaohui Yang and Haiwei Dong for their assistance in ultrasound examination.

Funding

This work was supported by the National Natural Science Foundation of China (grant number 81472761 to GL) and the Natural Science Foundation of Tianjin City (grant number 14JCYBJC25300 to GL).

Conflict of interest

The authors declare no conflict of interest.

References
[1]
Oh SR, Cho YJ, Han M, Bae JW, Park J, Rha S. Uterine lipoleiomyoma in peri or postmenopausal women. Journal of Menopausal Medicine. 2015; 21: 165–170.
[2]
Scurry J, Hack M. Leiomyosarcoma arising in a lipoleiomyoma. Gynecologic Oncology. 1990; 39: 381–383.
[3]
McDonald AG, Dal Cin P, Ganguly A, Campbell S, Imai Y, Rosenberg AE, et al. Liposarcoma arising in uterine lipoleiomyoma: a report of 3 cases and review of the literature. American Journal of Surgical Pathology. 2011; 35: 221–227.
[4]
Tyagi N, Tyagi R, Griffin Y. Uterine lipolemyoma. BMJ Case Reports. 2014; 2014: bcr2014207763.
[5]
Terada T. Large lipoleiomyoma of the uterine body. Annals of Diagnostic Pathology. 2012; 16: 302–305.
[6]
Raga F, Cholvi S, Esquembre MJ, Boigues D, Lucas C, Bonilla-Musoles F. Three-dimensional ultrasound radiance mode imaging of a uterine lipoleiomyoma. Medical Ultrasonography. 2016; 18: 247–249.
[7]
Nayal B, Somal P, Rao A, Kumar P. Uterine lipoleiomyoma: a case report of a rare entity. International Journal of Applied and Basic Medical Research. 2016; 6: 134–136.
[8]
Chu C, Tang Y, Chan TA, Wan Y, Fung K. Diagnostic challenge of lipomatous uterine tumors in three patients. World Journal of Radiology. 2012; 4: 58–62.
[9]
Nazir HM, Mehta S, Seena CR, Kulasekaran N. Uterine lipoleiomyoma: a report of two cases. Journal of Clinical Imaging Science. 2017; 7: 26.
[10]
Johari B, Koshy M, Sidek S, Hanafiah M. Lipoleiomyoma: a rare benign tumour of the uterus. BMJ Case Reports. 2014; 2014: bcr2014205814.
[11]
Carvalho JF, Cubal A, Torres S, Morgado A, Oliveira C, do Carmo O. Preoperative diagnosis of a uterine lipoleiomyoma using transvaginal ultrasound: a case report of an unusual entity. Journal of Obstetrics and Gynaecology. 2014; 34: 281–282.
[12]
Fujiwaki R, Ohnuma H, Miura H, Sawada K. Uterine lipoleiomyoma in an elderly patient: a case report. Archives of Gynecology and Obstetrics. 2008; 277: 471–474.
[13]
Avritscher R, Iyer RB, Ro J, Whitman G. Lipoleiomyoma of the uterus. American Journal of Roentgenology. 2001; 177: 856.
[14]
Karaman E, Çim N, Bulut G, Elçi G, Andıç E, Tekin M, et al. A Case of giant uterine lipoleiomyoma simulating malignancy. Case Reports in Obstetrics and Gynecology. 2015; 2015: 926961.
[15]
Villanueva AJ, Martínez-Noguera A, Pérez C, Clotet M, Oliva E. Uterine myolipoma: CT and us. Abdominal Imaging. 1993; 18: 402–403.
[16]
Loffroy R, Nezzal N, Mejean N, Sagot P, Krausé D. Lipoleiomyoma of the uterus: imaging features. Gynecologic and Obstetric Investigation. 2008; 66: 73–75.
[17]
Ghosh B, McKeown B, Gumma A. Lipoleiomyoma. BMJ Case Reports. 2011; 2011: bcr0820114577.
[18]
Oppenheimer DA, Carroll BA, Young SW. Lipoleiomyoma of the uterus. Journal of Computer Assisted Tomography. 1982; 6: 640–642.
[19]
Maebayashi T, Imai K, Takekawa Y, Sasaki J, Otsuka H, Katsura Y, et al. Radiologic features of uterine lipoleiomyoma. Journal of Computer Assisted Tomography. 2003; 27: 162–165.
[20]
Arikawa S, Uchida M, Shinagawa M, Tohnan T, Hayabuchi N. Significance of the “beak sign” in the differential diagnosis of uterine lipoleiomyoma from ovarian dermoid cyst. Kurume Medical Journal. 2006; 53: 37–40.
[21]
Tsushima Y, Kita T, Yamamoto K. Uterine lipoleiomyoma: MRI, CT and ultrasonographic findings. British Journal of Radiology. 1997; 70: 1068–1070.
[22]
Prieto A, Crespo C, Pardo A, Docal I, Calzada J, Alonso P. Uterine lipoleiomyomas: us and CT findings. Abdominal Imaging. 2000; 25: 655–657.
[23]
Lehrman BJ, Nisenbaum HL, Glasser SA, Najar D, Rosen M. Uterine myolipoma. Magnetic resonance imaging, computed tomographic, and ultrasound appearance. Journal of Ultrasound in Medicin. 1990; 9: 665–668.
[24]
Chibisheva V, Antovska V, Trajanova M, Dabeski D, Jovanovic R, Kijajova I. Vascular lipoleiomyoma of the uterus: an unusual case. Medical Archives. 2016; 70: 473–476.
[25]
Akbulut M, Gündoğan M, Yörükoğlu A. Clinical and pathological features of lipoleiomyoma of the uterine corpus: a review of 76 cases. Balkan Medical Journal. 2014; 31: 224–229.
[26]
Aung T, Goto M, Nomoto M, Kitajima S, Douchi T, Yoshinaga M, et al. Uterine lipoleiomyoma: a histopathological review of 17 cases. Pathology International. 2004; 54: 751–758.
[27]
Kiuchi K, Hasegawa K, Ochiai S, Kosaka N, Kuroda H, Kaji Y, et al. Liposarcoma of the uterine corpus: a case report and literature review. Gynecologic Oncology Reports. 2018; 26: 78–81.
[28]
Gaskin CM, Helms CA. Lipomas, lipoma variants, and well-differentiated liposarcomas (atypical lipomas): results of MRI evaluations of 126 consecutive fatty masses. American Journal of Roentgenology. 2004; 182: 733–739.
[29]
Sun S, Bonaffini PA, Nougaret S, Fournier L, Dohan A, Chong J, et al. How to differentiate uterine leiomyosarcoma from leiomyoma with imaging. Diagnostic and Interventional Imaging. 2019; 100: 619–634.
[30]
Matsuda M, Ichimura T, Kasai M, Murakami M, Kawamura N, Hayashi T, et al. Preoperative diagnosis of usual leiomyoma, atypical leiomyoma, and leiomyosarcoma. Sarcoma. 2014; 2014: 498682.
[31]
Yamaguchi M, Kusunoki S, Hirayama T, Fujino K, Terao Y, Itakura A. Case of leiomyosarcoma arising from subserosal leiomyoma. Journal of Obstetrics and Gynaecology Research. 2019; 45: 1944–1947.
[32]
Holzmann C, Saager C, Mechtersheimer G, Koczan D, Helmke BM, Bullerdiek J. Malignant transformation of uterine leiomyoma to myxoid leiomyosarcoma after morcellation associated with ALK rearrangement and loss of 14q. Oncotarget. 2018; 9: 27595–27604.
[33]
Mittal KR, Chen F, Wei JJ, Rijhvani K, Kurvathi R, Streck D, et al. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas. Modern Pathology. 2009; 22: 1303–1311.
[34]
Giannella L, Delli Carpini G, Montik N, Verdecchia V, Puccio F, Di Giuseppe J, et al. Ultrasound features of a uterine perivascular epithelioid cell tumor (PEComa): case report and literature review. Diagnostics. 2020; 10: 553.
Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Share
Back to top